Clinical trials: Hair Disease
Sensorineural Hearing Loss, Tinnitus
Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss
The HEAR-RESTORE study is an exploratory clinical research program designed to evaluate new diagnostic and regenerative approaches for individuals experiencing inner ear injury, tinnitus, and temporary or permanent hearing loss.
- Conditions
- Sensorineural Hearing Loss, Tinnitus, Acoustic Trauma, Inner Ear Injury
- Trial name
- HEAR-RESTORE (NCT07472023)
- Testing
- Audiologic Monitoring, Investigational Regenerative Pharmacologic Therapy, Stem Cell Regenerative Therapy
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Truway Health, Inc.
Androgenetic Alopecia
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.
- Trial name
- NCT02279823
- Testing
- CB-03-01 solution, Minoxidil Solution 5%
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- Intrepid Therapeutics, Inc.
Androgenetic Alopecia
Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients
This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr.
- Trial name
- NCT07429253
- Testing
- Secretome, Platelet-Rich Plasma (PRP) Injections
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Hypertrichosis, Alopecia
Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth
A study to investigate clinical safety and effect on hair growth of FOL-005 in healthy volunteers. The study is divided in two parts, a single ascending dose (SAD) part and a multiple dose (MD) part.
- Conditions
- Hypertrichosis, Alopecia, Hirsutism
- Trial name
- NCT02793557
- Testing
- FOL-005
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Follicum AB
Trichotillomania
Technology Assisted Treatment for Trichotillomania
The investigators are testing two digital health interventions for trichotillomania (TTM), via a randomized trial design.
- Trial name
- NCT05118633
- Testing
- Keen2 bracelet, Reminder bracelet, Keen2 app
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- HabitAware Inc.
Alopecia, Alopecia, Androgenetic
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Trial name
- NCT01904721
- Testing
- Bimatoprost Solution 1, Bimatoprost Solution 2, Bimatoprost Vehicle
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- Allergan
Alopecia Areata
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).
- Trial name
- Allegro2a (NCT04517864)
- Testing
- PF-06651600
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 71 people
- Sponsor
- Pfizer
Hair Thinning
Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair
The objective of this study is to assess the effectiveness and safety of a novel dietary supplement containing botanical ingredients for hair thinning in men over the course of six months of continuous daily usage.
- Trial name
- NCT05339958
- Testing
- Nutrafol® Men Hair Growth Nutraceutical
- Where
- 2 sites in United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Nutraceutical Wellness Inc.
Prevention of Chemotherapy-induced Myelosuppression
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
This is a Phase 1b open-label, single arm, multicenter, study of ALRN-6924 as a chemoprotection agent in patients with TP53-mutated HER2- breast cancer (stages IIa to IIIb) receiving neoadjuvant or adjuvant chemotherapy with…
- Trial name
- NCT05622058
- Testing
- ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
- Where
- 14 sites in United States, Bosnia and Herzegovina and 2 more
- Volunteers
- 6 people
- Sponsor
- Aileron Therapeutics, Inc.
Skin Condition, Hair Fragility
Assessment of Anti-aging Efficacy of Marine Collagen Peptides
To assess the anti-aging efficacy of Marine Collagen Peptides on skin, hair and finger nails for human
- Conditions
- Skin Condition, Hair Fragility, Nails, Ingrown
- Trial name
- NCT06306105
- Testing
- Marine Collagen Peptides
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Androgenic Alopecia
Androgenic Alopecia TH07 Clinical Trial
The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety.
- Trial name
- MATT (NCT07435012)
- Testing
- TH07, Minoxidil 5% Topical Solution
- Where
- Canada
- Volunteers
- 420 people
- Sponsor
- Triple Hair Inc
Alopecia, Male Pattern Hair Loss
To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males
The study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of GT20029 solution.
- Trial name
- NCT06692465
- Testing
- GT20029 Tincture
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Alopecia Areata
Long-Term PF-06651600 for the Treatment of Alopecia Areata
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata.
- Trial name
- ALLEGRO-LT (NCT04006457)
- Testing
- PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
- Where
- 144 sites in United States, Argentina and 15 more
- Volunteers
- 1,057 people
- Sponsor
- Pfizer
Hypotrichosis
Efficacy and Safety of Dallixa® Eyelash Serum in Idiopathic Eyelash Hypotrichosis
Efficacy and Safety of Dallixa® Eyelash Serum in Idiopathic Eyelash Hypotrichosis
- Trial name
- NCT07776028
- Testing
- dermo cosmetic product
- Where
- Turkey (Türkiye)
- Volunteers
- 37 people
- Sponsor
- Quantum Aesthetics Cosmetics
Androgenetic Alopecia, Hair Loss
Treatment of Androgenic Alopecia in Males
The purpose of this study is to evaluate the change in terminal hair count at 16 and 26 weeks compared to baseline measurements.
- Conditions
- Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
- Trial name
- NCT00947219
- Testing
- HairMax LaserComb, Control device
- Where
- 3 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Alopecia Areata
Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser
Alopecia areata (AA) an autoimmune disorder of hair follicles results in varying degrees of scalp, facial and body hair loss. Clinically, patients' presentation varies from patchy circumscribed scalp involvement to total body and…
- Trial name
- NCT06239324
- Testing
- Latanoprost
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Egymedicalpedia
Alopecia Areata
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03898479
- Testing
- CTP-543
- Where
- 91 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Alopecia Areata
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
This is a parallel, Phase 2 multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study to investigate the efficacy and safety of subcutaneous (SC) injections of amlitelimab treatment as monotherapy in…
- Trial name
- NCT06444451
- Testing
- Amlitelimab
- Where
- 74 sites in United States, Argentina and 14 more
- Volunteers
- 166 people
- Sponsor
- Sanofi
Gut Dysbiosis, Telogen Effluvium
Gut Microbiota and Trichoscopic Changes in Women With Telogen Effluvium on a Multifactorial Drinkable Nutraceutical: A Retrospective Observational Study
Telogen effluvium (TE) is a common cause of diffuse, non-scarring hair shedding in women. It is often triggered by physiological stress, nutritional deficiencies, illness or hormonal changes.
- Conditions
- Gut Dysbiosis, Telogen Effluvium, Hair Loss
- Trial name
- NCT07869199
- Testing
- Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women.
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Olistic Research Labs S.L.
Alopecia Areata
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
- Trial name
- NCT07133308
- Testing
- Deuruxolitinib
- Where
- 64 sites in United States, Canada
- Volunteers
- 355 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.